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Organophosphates are neurotoxic compounds that inhibit acetylcholinesterase
producing excess cholinergic stimulation. This produces various toxic signs including
excitotoxic neuronal damage. Oximes can be used as a treatment for organophosphate
poisoning by reactivating inhibited acetylcholinesterase. Traditional oximes do not
penetrate the blood-brain barrier, limiting protection of the central nervous system.
Novel, brain-penetrating oximes have the potential to protect the brain from
organophosphate induced damage. Adult male rats were used to examine the ability of
model organophosphates to produce neuropathology and the ability of novel oximes to
prevent this damage. Additionally, adult male rats were used to examine changes in gene
expression of the MAP kinase system resultant of treatment with model
organophosphates and novel oximes. Results of these experiments support that the model
organophosphates can be used to study neurodegeneration, the novel oximes may prevent
neurodegeneration, and both organophosphates and novel oximes affect expression of
MAP kinase genes.
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CHAPTER I
INTRODUCTION
1.1

Brief History of Organophosphates
Organophosphates (OPs) consist of a diverse group of compounds having a

variety of uses including: pesticides, fire retardants, plasticizers, and chemical warfare
agents (CWAs). The first documented synthesis of an organophosphate was the creation
of methyl phosphor chloride by Von Hoffman in 1837. Several developments by other
scientists followed in the following years, but the most notable occurred in 1934 when
the German chemist Gerhard Schrader was tasked with developing pesticides. His group
developed roughly 2000 different compounds including parathion, tabun, sarin, and
soman. While parathion could be used as a pesticide, the toxicities of tabun, sarin, and
soman were such that they could not be safely used for this purpose. This toxicity did
provide the potential for their use as CWAs. Due to this potential, tabun and sarin were
manufactured in a factory outside Duhernfurt, for potential use in the war effort.
Following the end of the war, large quantities of these chemicals were seized by the
Allies. The chemicals developed by the Germans were given code names beginning with
“G” to signify German. Research by Allies scientists after the war produced additional
compounds given codes starting with “V” to signify victory. VX (S-2 diisopropylamino
O-ethylmethylphosphonothioate) was developed by British scientists in 1952. The
Russians produced a similar compound called VR (N, N-diethyl-2-methyl-2methylpropoxy phosphorylsulfanylethanamine). Other agents in the V series are VE (S-21

diethylaminoethyl O-ethylethylphophonothioate), VM (2-ethoxy-methylphosphoryl
sulfanyl-N, N-diethylethanamine), and VG (2-diethoxyphosphorylsulfanyl-N, Ndiethylethanamine). Following WWII, development of OPs as pesticides continued and
their popularity only increased after use of organochlorine compounds was banned
(Soltaninejad & Shadnia, 2014). In the United States, organophosphates constituted more
than 70% of all pesticides used during some years of the 1980s and 1990s. This use has
since declined with the advent of newer, less toxic pesticides (U. S. Environmental
Protection Agency, 2007).
Despite significant production during World War II, use of organophosphates in
warfare did not occur until the Iran-Iraq War (1980-1988). The United Nations
confirmed that Iraq used tabun and sarin on both Iranian soldiers and civilians. It is
estimated that through multiple deployments of OP and sulfur mustard CWAs, over
100,000 people were poisoned during the Iran-Iraq War. During the First Persian Gulf
War, while CWAs were not used, US service members may have been exposed to sarin
and cyclosarin following the destruction of Iraqi munitions. OP CWAs have also been
used in terrorist attacks such as the release of sarin by Aum Shinrikyo in the Tokyo
subway that resulted in 11 deaths and the poisoning of 5500 others. (Soltaninejad &
Shadnia, 2014). Most recently, sarin has been deployed in Syria in 2013 and 2017 by the
Assad regime resulting in many civilian deaths (Adamson & Vasilyeva, 2017; Loveluck,
2017).

2

1.2

Properties of Organophosphates
Organophosphates used as pesticides and CWAs are potent anticholinesterases

that phosphorylate acetylcholinesterase (AChE) inhibiting its ability to hydrolyze the
neurotransmitter acetylcholine (ACh). This leads to an excess of ACh in synapses and
neuromuscular junctions. Accumulation of ACh affects nicotinic and muscarinic
acetylcholine receptors both in the peripheral and central nervous systems. These
supraphysiological levels of cholinergic stimulation produce an array of toxic signs in
exposed individuals including: excessive secretions from bronchial, salivary, ocular, and
intestinal glands, miosis, bronchospasm, bradycardia, muscle fasciculations, respiratory
suppression, seizures, and death (Watson et al., 2009).
ACh is responsible for chemical signal transduction of autonomic neuronal
ganglia, parasympathetic innervation of organs, sympathetic innervation of sweat glands,
motor innervation of skeletal muscles, and signal conduction between central nervous
system (CNS) neurons. It is released from axonic terminals of cholinergic neurons into
the synapses following the conductance of an action potential down the axon. It is
released from vesicles into the synapse where it interacts with ACh receptors on the postsynaptic membrane transmitting the signal to the target cell. ACh within the synapse is
quickly hydrolyzed by AChE to terminate signal transduction. To accomplish hydrolysis,
ACh temporarily binds to AChE. The positive charge of the quaternary nitrogen in the
choline group electrostatically binds to an anionic site assisted by auxiliary binding of the
adjacent methyl groups. Subsequently the carbonyl carbon of acetate covalently binds to
the esteratic site of AChE. Following this binding, the ester linkage between acetate and
choline is broken and choline leaves the protein. Finally, a reaction between water and
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acetate occurs and acetic acid is released returning AChE to its active form (Gallo &
Lawryk, 1991).
Organophosphates’ effects on AChE result from their esteric structure. B-class
esterases such as AChE react with OPs but become persistently phosphylated preventing
them from performing their normal actions on other esters such as ACh. The phosphorus
atom of the OP binds to the esteratic site and the OP may or may not have a positive
charge in the acidic group to interact with the anionic site. The acidic leaving group
separates from the rest of the OP, which is left bound to AChE. Where removal of the
normal substrate for this enzyme would occur in less than a second, hydrolysis of the
bound OP can take more than 1000 hours in some of the more persistent compounds. The
time needed for hydrolysis is a function of the compound left attached to AChE and is not
affected by the leaving group (Gallo & Lawryk, 1991).
While initially slowly reversible, OPs “age” at a variable rate depending on the
compound. Aging is the result of loss of an alkyl or alkoxy group that irreversibly binds
the OP to the AChE molecule (Watson et al., 2009). Aging of phosphorylated AChE is
most easily observed when a reactivator such as a nucleophilic oxime used to reverse the
phosphorylation cannot remove the portion of OPs that are aged. Reactivation of
phosphorylated AChE becomes progressively less efficient the longer that the
phosphorylation has been present with an increasing amount of the enzyme being
completely resistant to reactivation. This aging takes place at an exponential rate. The
hydrolysis of an alkyl or alkoxy group leaves a monoalkoxy moiety that cannot be
removed by nucleophilic attack. The function of an irreversibly inhibited AChE molecule
can only be restored by producing a new molecule of AChE to take its place. This takes
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place in different manners in different tissues. Red blood cells lack the ability to
synthesize more cholinesterase, so circulating cholinesterase can only be restored through
erythropoiesis in the bone marrow. Plasma cholinesterase is restored by the liver. AChE
within the brain is synthesized in the neuronal cell body and transported by axonal flow
to the synaptic terminals, this being indicated by regeneration of synaptosomal AChE
occurring 24 hours after regeneration within the microsomal fraction (Gallo & Lawryk,
1991; Austin & James, 1970).
With the esteratic site occupied, AChE cannot degrade ACh. Continuing release
of ACh within the synaptic cleft produces an increased concentration of ACh.
Accumulation of ACh produces the majority of the effects seen with organophosphate
poisoning. These signs include sweating, miosis, lacrimation, salivation, respiratory tract
secretion, vomiting, muscle fasciculations, cardiac arrhythmia, heart block, seizures, and
coma. Death can occur within 5 minutes of exposure with high doses of the most toxic
OPs. Death due to OP poisoning is generally due to respiratory failure but may result
from cardiac failure as well. CNS involvement is not required but can contribute to
lethality. Respiratory failure is likely a result of inhibition of the respiratory centers in the
brainstem, bronchoconstriction, bronchial secretions, and paralysis of the respiratory
muscles (Costa, 2008).
1.3

Therapeutic Intervention
Therapy of OP exposure consists of several components that work through

different mechanisms. Should immediate future organophosphate exposure be expected,
pretreatment therapies can decrease the severity of OP intoxication. Following exposure,
direct anticholinergic treatments can be used to combat the effects of the OP. Finally,
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oximes directly target OP molecules bound to AChE to restore its normal function
(Masson, 2011).
1.3.1

Pretreatments
Prophylactic pretreatments consist of two general categories, reversible AChE

inhibitors that temporarily bind AChE so that it is unavailable for OP binding and
bioscavengers that inactivate OP molecules before they are able to react with
physiological targets. The reversible AChE pretreatment currently in use is
pyridostigmine bromide. It is a carbamate that transiently carbamylates AChE protecting
it from phosphorylation. It does not cross the blood-brain barrier (BBB), and therefore
provides no CNS protection. Use of pyridostigmine along with exposure to several other
stressors has been associated with development of Gulf War Syndrome (Masson, 2011).
The body contains a variety of compounds in its tissues that are able to detoxify
OPs and with low exposures may prove almost completely protective. It is also possible
that exogenous bioscavengers might be able to be administered for protection against OP
exposure. Bioscavengers may be able to react with OP compounds either
stoichiometrically or catalytically. Butyrylcholinesterase (BuChE), likely one of the most
important endogenous bioscavengers, is present in human plasma at a concentration of
about 50 nM. It serves no known biological function and is able to stoichiometrically
(1 BuChE: 1 OP molecule) react with OPs in the bloodstream. Limited amounts can be
produced for exogenous administration to provide more protection than is normally
present in the human bloodstream. There are natural enzymes within the human body that
have the potential to act as catalytic bioscavengers of OPs. The most promising of these
is paraoxonase-1 (PON-1). It is produced by the liver and is able to hydrolyze some OP
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molecules at a rapid rate. Attempts have been made to produce mutant of PON-1 that are
more catalytically efficient and potentially protective against nerve agents (Masson,
2011).
1.3.2

Anticholinergics
Atropine is a muscarinic acetylcholine receptor antagonist that helps to decrease

the effects of ACh in muscarinic synapses (Masson, 2011). It accomplishes this by
blocking the binding of ACh to muscarinic receptors in smooth and cardiac muscle,
glands, peripheral ganglia, and the CNS. Both atropine and AChE compete for a common
binding site on these receptors. Due to its competitive nature, this inhibition can be
overcome with sufficient ACh concentrations. Atropine counteracts many of the ill
effects of OPs including bronchoconstriction, heart block and excess glandular secretions.
Its effects begin within 1-4 minutes of administration and peak within 8 minutes (Brown
& Taylor, 2006; Gallo & Lawryk, 1991).
1.3.3

Oximes
Oximes are a group of compounds that can be used to reactivate phosphorylated

AChE. This ability comes from their oximate anion, which is strongly nucleophilic at a
physiological pH (Masson, 2011). Nucleophilic attack by oximes releases the bound OP
moieties from AChE (Gallo & Lawryk, 1991). There is no recognized best oxime as their
reactivation potential differs depending on which OP has phosphorylated AChE. Once an
AChE bound OP has aged oximes no longer have the ability to remove the group.
Currently used oximes such as 2-PAM, obidoxime, and HI-6 are quaternary
pyridinium oximes. These oximes are able to reactivate peripheral AChE restoring
respiratory function and decreasing mortality. They are strongly charged and thus unable
7

to cross the BBB. This prevents them from attenuating CNS damage caused by OP
intoxication. Various attempts have been made to facilitate delivery to the brain, but none
have been successful enough for field use (Masson, 2011).
1.3.4

Intoxication Treatment
In cases of organophosphate exposure, treatment differs somewhat depending

upon the level of intoxication. In less severe cases of OP intoxication, atropine sulfate is
administered first. Once atropine has been administered, decontamination of any
remaining source of OP will prevent further entry of the chemical into the body. Should
the victim fail to respond to atropine alone, pralidoxime chloride (2-PAM) would be
administered. Beyond that, treatment is symptomatic. In more severe cases, artificial
respiration is the most immediate priority. Next, multiple higher doses of atropine than
used in less severe exposures are administered followed by 2-PAM therapy. After
medications have been administered, decontamination and symptomatic treatment can be
performed (Gallo & Lawryk, 1991).
1.4

Novel Oximes
While conventional pyridinium oximes such as 2-PAM are effective at decreasing

mortality in those exposed to high OP doses, they have little to no ability to cross the
blood brain barrier and reactivate AChE within the central nervous system. It is believed
that an oxime that could effectively cross the BBB and reactivate AChE within the CNS
could both increase chances of survival and prevent or attenuate seizures and resultant
brain injury in those exposed to these compounds, reducing the burden of neurological
disease in these individuals.
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A series of novel pyridinium oximes (US patent 9,277,937) with the potential to
penetrate the blood brain barrier has been invented by Dr. Howard Chambers in the
Department of Biochemistry, Molecular Biology, Entomology and Plant Pathology at
Mississippi State University. These novel oximes have shown promising results in
reactivating brain AChE in both in vitro and in vivo rat studies. This testing has been
conducted using two highly relevant surrogates of sarin and VX, nitrophenyl isopropyl
methyl phosphonate (NIMP) and nitrophenyl ethyl methyl phosphonate (NEMP),
respectively (Meek et al., 2012). Oximes were administered at the time of peak brain
AChE inhibition in order to ensure that decreased inhibition of brain AChE was the result
of oxime entry into the brain and not due to the OP being bound by reactivated peripheral
AChE, decreasing the amount of OP able to reach the brain. In the in vitro studies, some
oximes have achieved AChE reactivations of 70%. In vivo studies were subsequently
conducted on oximes that reached a minimum of 40% in vitro reactivation. The most
successful of these oximes, Oxime 20, achieved AChE reactivation of 25% in brain tissue
at 30 min post oxime administration. In this same in vivo study, 2-PAM produced no
AChE reactivation within the brain. While degree of lipophilicity was not related to
efficacy at reactivating AChE, all of the tested oximes were more lipophilic than 2-PAM,
possibly explaining their ability to reactivate brain AChE (Chambers, Chambers, Meek,
& Pringle, 2013). Further studies produced in vivo brain AChE reactivation of up to 35%
at 2 hours post oxime administration. Oxime 20 (the most effective reactivator of AChE
within the brain thus far) has levels of peripheral AChE reactivation approaching that of
2-PAM, 40 to 45% compared to 55 to 60%. Studies of seizure attenuation and survival
using lethal doses of NIMP and NEMP demonstrated the protective effect of both Oxime
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20 and Oxime 1. Both of these oximes caused termination of seizures by 6 hours while
rats treated with 2-PAM were still displaying seizure activity at 8 hours. Additionally, the
novel oximes produced higher survival rates than 2-PAM (Chambers et al., 2016).
Studies have also been performed of astrocyte glial fibrillary acidic protein
(GFAP) expression in rat brains following exposure to nerve agent surrogates as an
indicator of activation of astrocytes, which should indicate neuroinflammation. Seizure
behavior and increased GFAP expression of both NIMP and NEMP treated rats were
similar to those of the positive control, kainic acid. GFAP levels in those rats
subsequently treated with Oxime 20 showed lower levels of GFAP relative to OP alone,
similar to the control, indicating that brain inflammation would likely be greatly reduced
or eliminated in subjects receiving this therapy. In contrast to Oxime 20, 2-PAM was not
observed to affect level of GFAP expression in this study.
1.5

Research Summary
To further study the potential use of these novel oximes, the research described in

this thesis was undertaken. This work sought to further measure the sparing of neuronal
injury resultant of OP intoxication when these oximes were employed. The first goal of
this research, as will be discussed in Chapter 2, was to compare degree of
neurodegeneration seen in the brains of rats dosed with the sarin surrogate NIMP or
paraoxon to those of rats that were dosed with NIMP but subsequently treated with one of
our lead novel oximes, Oxime 20. The next goal was to further explore how the cells of
the CNS respond physiologically to NIMP administration and treatment of NIMP
intoxication with Oxime 20, Oxime 1, and 2-PAM. Genetic regulation of MAP kinase
was selected for this as this system mediates cellular response to a variety of stimuli and
10

may provide insight into how these cells will respond to exposure to these compounds.
This experiment will make up Chapter 3 of this document.
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CHAPTER II
NEURODEGENERATION FOLLOWING ORGANOPHOSPHATE AND NOVEL
OXIME TREATMENT
2.1

Introduction
Organophosphates, especially those used as pesticides or CWAs, function as

potent cholinesterase inhibitors capable of producing various toxic signs including
hypersecretion, convulsions, coma, and death. Depending on dose and agent of exposure,
seizures can progress rapidly into full status epilepticus that can produce significant brain
damage. Work in rats using soman shows that acetylcholinesterase inhibition leads to a
build-up of acetylcholine, which causes excessive cholinergic stimulation resulting in
seizures, the first 5 minutes of which are completely dependent on cholinergic
stimulation. During the time from 5 minutes to 40 minutes after induction of seizures,
control of seizure activity begins to transition from the cholinergic system to other
neurotransmitters (Shih & McDonough, 1997). Once seizures begin, extracellular
glutamate levels increase and serve as the main source of seizure stimulation (Lallement
et al, 1991). Past 40 minutes of seizures, the cholinergic system no longer serves as the
primary controller of seizure activity, and excitatory amino acids such as glutamate are
the main source of seizures (Shih & McDonough, 1997; Eisenkraft, Falk, & Finkelstein,
2013). As a result of these prolonged seizures, excitotoxic neural pathology occurs
following exposure to high dosages of organophosphate anticholinesterases
(McDonough, Dochterman, Smith, & Shih, 1995). Status epilepticus resulting from OP
12

exposure has been documented to produce a prolonged elevation of calcium within the
brain that could be indicated in the excitotoxic neuropathology due to the important role
that calcium ions play as second messengers in neurodegenerative pathways (Deshpande,
Carter, Blair, & DeLorenzo, 2010; Deshpande, Blair, Phillips, & DeLorenzo, 2016b).
This damage results in some cells dying within the first 24 hours. During this same time
course, some neurons develop an eosinophilic, degenerate appearance. These neurons
will degenerate and die in a period of time ranging from 2 weeks to 2 months (Collombet
et al., 2011). On closer examination, these degenerating neurons display necrotic,
apoptotic, and hybrid forms of cell death. One study of ultrastructural morphology
demonstrated at least 11 distinct morphological types of degrading neurons displaying
varying degrees of both apoptotic and necrotic characteristics as a result of soman
exposure (Baille et al, 2005). The death of these degenerating neurons can provide a
source of further damage lasting out to three months post-OP exposure. Beyond 3
months, there should be no further degenerate neurons present (Collombet et al., 2011).
Studies of organophosphate induced neurodegeneration show widespread, highly
variable neuronal damage in the brains of exposed animals. Of the damage seen with
these compounds, six regions most consistently displayed neurodegeneration. These
regions are the piriform cortex, hippocampus, thalamus, amygdala, cerebral cortex, and
caudate/putamen. The piriform cortex, amygdala, and hippocampus tend to most
frequently display evidence of neuropathology, while the piriform cortex and
hippocampus are generally the most severely damaged of these regions. Within these
regions of the brain, certain subsets of cells seem to be more sensitive to the effects of
OPs. In the piriform cortex, the pyramidal cells are primarily affected. The CA1 and CA2
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regions of the hippocampus suffer more damage than the CA3. The medial and dorsal
nuclei of the thalamus generally suffer more damage than other areas within this region.
Damage in the cerebral cortex is usually less than other areas of the brain with occasional
necrosis of pyramidal cells. Damage to the caudate/putamen is generally both less
frequent and less severe than other areas of the brain (McDonough, Jaax, Crowley, May,
& Modrow, 1989; McDonough et al., 1995). The specificity of this excitotoxic damage in
these regions could be explained by the dense association of cholinergic neurons and the
large number of cholinergic projections (Chen, 2012).
Aside from direct damage to the neurons resulting from seizures, the subsequent
metabolic deregulation and cell death result in activation of microglia and astrocytes
producing neuroinflammation (Collombet et al., 2011). Glutamate itself can contribute to
this activation of the immune system. Evidence exists that T cells can be activated
directly by glutamate and subsequently activate microglia by the secretion of cytokines
(Eisenkraft et al., 2013). These activated microglia and astrocytes along with invading
macrophages produce inflammatory cytokines for several days following neuronal injury.
These inflammatory cytokines, of which microglia are the primary source, include tumor
necrosis factor α (TNFα), interleukin 1β (IL1β) and interleukin 6 (IL6). Astrocytes
additionally produce neurotrophic factors and growth factors including ciliary
neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), basic fibroblast
growth factor (FGF-2), nerve growth factor (NGF) and vascular endothelial growth factor
(VEGF). These cytokines contribute to the survival of degenerating neurons and also
promote glial scar formation (Collombet et al., 2011).
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Astrocytes are glial cells that serve several important functions following brain
injury. Several of these functions, including taking up excess extracellular glutamate and
eliminating reactive oxygen species, protect neurons after an acute injury. They can also
serve a role in the inflammatory processes that occur following an injury by secreting an
array of inflammatory cytokines. Following injury and destruction of neurons, astrocytes
can form glial scars within the brain as well as assist in remodeling of the extracellular
matrix. Astrocytes also produce neurotrophic factors that assist in survival and
remodeling of neurons following injury (Chen & Swanson, 2003). In rodents, astrocytes
are typically activated within 3 days post-traumatic brain injury, and this activation can
last for several weeks (Collombet et al., 2007).
Microglia are activated in a timespan from hours to days following a
neurodegenerative event to serve as the main inflammatory cell within the brain. Once
activated, their morphology and antigen expression begin to become more macrophagelike, and they exhibit some functions similar to macrophages such as phagocytosis of
cellular debris and secretion of inflammatory cytokines (Zimmer, Ennis, & Shipley,
1997; Simoni et al., 2000).
The damage produced in the brain as a result of OP intoxication can lead to longlasting behavioral and cognitive impairment (Filliat et al., 2006). Current treatment for
OP intoxication in the United States involves the use of atropine, anticonvulsants, and the
oxime 2-PAM. Atropine has anticholinergic effects, antagonizing excess ACh at
muscarinic receptors. Anticonvulsants such as diazepam are capable of terminating
seizures by acting on GABA receptors. Oximes act by transphosphorylating OP
molecules that are bound to AChE. This reactivates the AChE molecule and makes it
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available to degrade ACh. The currently approved oxime for the treatment of OP
intoxication in the U.S. is pralidoxime (2-PAM) (RamaRao, Afley, Acharya, &
Bhattacharya, 2014). While 2-PAM is effective at decreasing mortality in those exposed
to high OP doses, it has little to no ability to cross the blood brain barrier and reactivate
AChE within the CNS. It is believed that an oxime that could effectively cross the BBB
and reactivate AChE within the CNS could both increase chances of survival and prevent
or attenuate seizures and resultant brain injury in those exposed to these compounds,
reducing the burden of neurological disease in these individuals.
A series of novel phenoxyalkyl pyridinium oximes developed by Dr. Howard
Chambers at the Department of Biochemistry, Molecular Biology, Entomology and Plant
Pathology at Mississippi State University have been shown to have the potential to be
more effective than oximes currently available in both preventing mortality and
decreasing morbidity (in the form of brain damage) in rats exposed to high doses of OPs.
The novel oximes have shown promising results of reactivating brain AChE in both in
vitro and in vivo studies. This testing has been conducted using two highly relevant
surrogates of sarin and VX, nitrophenyl isopropyl methyl phosphonate (NIMP), first
described by Ohta et al. (2006), and nitrophenyl ethyl methyl phosphonate (NEMP), first
described by Fukuto & Metcalf (1958), respectively (Meek et al., 2012). Oximes were
administered at the time of peak brain AChE inhibition following a high sublethal dose of
organophosphate. This time was chosen to ensure that decreased inhibition of brain
AChE was the result of oxime entry into the brain and not due to the OP being bound by
reactivated peripheral AChE, decreasing the amount of OP able to reach the brain. In the
in vitro studies, some oximes have achieved AChE reactivations of 70%. In vivo studies
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were subsequently conducted on oximes that reached a minimum of 40% in vitro
reactivation. The most successful of these oximes, Oxime 20, achieved AChE
reactivation of 25% in brain tissue at 30 minutes post oxime administration. In this same
in vivo study, 2-PAM produced no AChE reactivation within the brain. While degree of
lipophilicity was not related to efficacy at reactivating AChE, all of the tested oximes
were more lipophilic than 2-PAM, possibly explaining their ability to reactivate brain
AChE (Chambers et al., 2013). Further studies produced in vivo brain AChE reactivation
of up to 35% at 2 hours post oxime administration. Those oximes that reactivated at least
20% of brain AChE attenuated seizures. Oxime 20 (the most effective reactivator of
AChE within the brain thus far) has levels of peripheral AChE reactivation approaching
that of 2-PAM, 40 to 45% compared to 55 to 60%. Treatment with these compounds has
been shown to produce survival rates comparable to or better than 2-PAM and attenuate
seizure like-behavior (Chambers et al., 2016).
Previous studies have been performed measuring GFAP expression in rat brains
following exposure to nerve agent surrogates and subsequent treatment with Oxime 20 as
an indicator of neurodegeneration. It was observed that GFAP expression in the piriform
cortex and dentate gyrus was significantly reduced in animals treated with Oxime 20 at 4
days post-exposure to NIMP or NEMP challenge relative to those that were not treated
with the novel oxime. Seizure behavior and GFAP expression of both NIMP and NEMP
treated rats were similar to those of the positive control, kainic acid. GFAP levels in those
rats subsequently treated with Oxime 20 showed decreased levels of GFAP, similar to the
control, indicating that brain damage would likely be greatly reduced in subjects
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receiving this therapy. In contrast to Oxime 20, 2-PAM was not observed to affect the
level of GFAP expression in that study.
This study was designed to further examine neural damage induced by the sarin
surrogate NIMP and paraoxon and explore the ability of the novel oximes to attenuate
this damage. Development of observable pathological signs is attributed to prolonged
seizure activity. Compounds that are able to prevent or attenuate seizures have been
shown to decrease resulting pathology (McDonough et al., 1995). For this study, lethal
doses of both NIMP and paraoxon were used in order to produce excitotoxic
neurodegeneration. Time delays of 1 hour between OP and oxime administration were
included to reflect the delay that would occur in actual poisoning events. As the brain can
tolerate about 45 min of seizures without appreciable neurodegeneration (Motte,
Fernandes, Baram, & Nehlig, 1998; Norwood et al., 2011), a 1 hour delay, reflecting the
observed 15 minute latent period and 45 minutes of seizures, is an approximate far end of
the therapeutic window needed for preventing brain damage. The test dosage of novel
oximes was 146 µmoles/kg, the molar equivalent of the approved therapeutic dosage of
2-PAM delivered in three auto-injectors. This dosage has been chosen because it would
best emulate treatment of human poisoning victims. The novel oximes chosen for this
study were Oxime 20 and Oxime 15, two of the most promising of the novel oximes.
Neurodegeneration was measured at both 24 hours and 4 days post-organophosphate
exposure. Twenty-four hours was chosen as to measure immediate excitotoxic
neurodegeneration while four days was selected to examine delayed neurodegeneration.
In the 24 hour brains, the hippocampus, amygdala, and piriform cortex were selected for
examination due to their high incidence and severity of neurodegeneration as noted in
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published literature. For 4 day animals, these regions were limited to the hippocampus
and piriform cortex due to their higher incidence of damage noted in published literature.
For measurement of neurodegeneration, FluoroJade B provides an easily
quantifiable, highly specific measure of dying neurons (Schmued, Albertson, & Slikker,
1997; Schmued & Hopkins, 2000). The use of this stain has been previously described in
animal model studies of nerve agent exposure (Myhrer, Andersen, Nguyen, & Aas, 2005;
Myhrer, Enger, & Aas, 2006; Apland et al., 2010; RamaRao et al., 2014; Li et al., 2011).
As this stain is not selective for either necrotic or apoptotic processes, it provides a
measure of total dying neurons, which are seen to display varying degrees of necrotic and
apoptotic properties (Baille et al., 2005). Additionally, as not all neurons that will die
from OP intoxication die immediately, staining these degenerating cells gives a measure
of the degree of neuronal death that is expected to occur but has not yet been completed.
To assist in identifying locations within the brain, DAPI was used as a counterstain to
indicate intact neurons (Giorgi et al., 2003). For verification of this staining method,
kainic acid was used as a positive control for neurodegeneration (Schmued & Hopkins,
2000).
2.2
2.2.1

Methods
Kainic Acid Treatments
Adult male (250-300g) Sprague Dawley rats were injected intraperitoneally with

10mg/kg kainic acid dissolved in sterile water. Initially, kainic acid sourced from
Cayman Chemical Companey (Ann Arbor, MI) was used for these treatments. Due to
lack of solubility and efficacy in producing seizures, kainic acid was purchased from
Tocris Bioscience (Bristol, UK), which proved highly soluble and effective in producing

19

seizures. Rats were monitored for 8 hours following initial injection and maintained by
animal facility staff for the next 24 hours to 4 days.
2.2.2

Organophosphate Treatments
Adult male (250-300g) Sprague Dawley rats were injected subcutaneously with

either a lethal dosage of the sarin surrogate NIMP (0.6 mg/kg), a lethal dosage of
paraoxon (0.8 mg/kg), or vehicle (Multisol). Oximes were given 30 minutes after
organophosphate administration. An intramuscular injection of 146 μmol/kg of either
Oxime 20, Oxime 15, or 2-PAM or vehicle (Multisol) was administered to rats in those
treatment groups. The first dose of atropine was also administered intramuscularly at a
dosage of 0.65 mg/kg at this time. Over the first 4 hours rats were administered up to 2
additional injections of atropine as necessary for control of peripheral cholinergic signs
with most rats receiving 3 injections total. Rats were monitored for 8 hours following
initial injection and maintained by animal facility staff for the next 24 hours to 4 days.
These procedures were performed under an approved Institutional Animal Care and Use
Committee protocol (#17248).
2.2.3

Perfusion and Sample Processing
Twenty-four hours or four days after treatment, rats were perfused by a protocol

adapted from (Gage, Kipke, & Shain, 2012). The rats were deeply anesthetized with
isoflurane and transcardially perfused with 0.9% sodium chloride until fluid ran clear
followed by 200 ml 4% paraformaldehyde. Skulls were removed and stored in
paraformaldehyde for 24 hours. At that point the brains were removed and placed in 25%
sucrose for 4 days to allow equilibration of sucrose into the brains to protect the
architecture of the tissue during freezing. At 4 days the brains were flash frozen in
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isopentane chilled over dry ice and then stored at -800 C until sectioning. The brains were
sectioned on a Leica HM560 cryostat with 25 μm sections taken 200 μm apart beginning
approximately 1.5 mm anterior to the bregma and ending 5mm posterior of the bregma.
These sections were mounted onto gelatin-coated slides and dried overnight at room
temperature.
2.2.4

Fluoro-Jade B Staining
The prepared slides were rehydrated in distilled water for 5 minutes prior to

staining. The slides were immersed in 0.06% potassium permanganate for 20 minutes on
an orbital shaker. This step serves to decrease background staining and decrease fading of
the stain from either age or exposure to light (Schmued et al., 1997). Slides were rinsed
three times for one minute each in dH2O. Slides were next placed in Fluoro-Jade B/DAPI
working solution in a light protected vessel on the orbital shaker for 30 minutes. This
working solution was created by adding to 165 ml 0.1% acetic acid: 7 ml Fluoro-Jade B
(Histo-Chem Inc., Jefferson AR) 0.01% stock solution and 3 ml DAPI (Thermo
Scientific, Rockford Il) 0.01% stock solution for a total working volume of 175 ml
(Schmued & Hopkins, 2000). Slides were again rinsed 3 times for 1 minute each in
dH2O. Sections were dehydrated by a graded alcohol series of 70%, 90%, and 100%
ethanol with 3 minutes in each alcohol followed by 5 minutes in xylene to clear sections
for mounting. DPX mounting media was used to coverslip the slides. Slides were then
air-dried in the dark and stored in a slide box until imaging.
2.2.5

Data Quantification
An Olympus U-MWB blue 450-480 nm excitation filter was used to induce

Fluoro-Jade B light emission. Slides were examined and images taken on an Olympus
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BX60 microscope at the 40X objective with a Lumenera Infinity 3 microscopy camera.
All samples were measured with the counter blinded to their treatment.
Twenty-four hour brains were examined first. In these samples, all regions of each
section were fully counted for Fluoro-Jade B staining. Any slide with greater than 100
counts was considered “too numerous to count” (TNTC). Following this study, it was
determined that this method was too thorough for those brains displaying significant
neurodegeneration while not providing any experimental benefit for those that were not,
so a different method was selected for 4 day animals.
For 4 day samples, three images were taken of high-power fields of the hilus of
the hippocampus, the CA1 region of the hippocampus, and the piriform cortex. This was
performed for each brain within sections that approximate -2.8 mm, -3.6 and -4.16mm
posterior to the bregma according to The Rat Brain in Stereotaxic Coordinates: Hard
Cover Edition (Paxinos & Watson, 2006). Fluoro-Jade B positive staining cells were
counted in each of these images and compiled into an Excel spreadsheet for data analysis.
ImageJ was used to assist in counting images containing high numbers of Fluoro-Jade B
positive cells (Schneider, Rasband, & Eliceiri, 2012). Counts were compiled into Excel
for analysis.

2.3

Results
Rats treated with kainic acid from Cayman produced signs of intoxication ranging

from mild depression to facial tremors. These rats showed no neurodegeneration upon
tissue processing. Rats treated with kainic acid from Tocris showed signs of seizure
activity including rearing and falling with forelimb clonus and death. The animals
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receiving this treatment displayed significant neurodegeneration upon tissue processing
verifying that the Fluoro-Jade B stain properly labeled degenerate neurons and that this
staining was present both at 24 hours and 4 days.
In total 115 rats were dosed per the organophosphate treatment protocol described
with perfusion and tissue preparation proceeding accordingly. Thirty-two of these
animals were perfused at a 24 hour time point, and 83 were perfused at a 4 day time
point.
In the 24 hour perfusion group, 4 brains were considered TNTC leaving 28 that
were fully counted. Due to differences in how many brains were available in each
treatment group and how many sections each brain produced, cells counted were
expressed both as total counts and counts per section (Table 2.1). Counts per section
ranged from 0.19 positive cells per section in the piriform cortex of the Paraoxon +
Oxime 20 group to 2.16 cells per section in the hippocampus of the Vehicle control. Due
to the very low number of counts in these brains and the fact that the vehicle control
counts were not appreciably different from any of the other treatments, the counts in
these groups are likely due to a basal stain uptake or a standard production of artifacts
from the staining methods employed.
The brains that were considered TNTC showed the distinct architecture of
degenerating neurons confirming that the Fluoro-Jade B staining was that of degenerating
neurons. The number of positive cells in each section from these brains far exceeded the
minimum 100 counts to be considered TNTC. Of the 4 brains counted as TNTC, 3 were
treated with Paraoxon 0.8 alone and 1 was treated with both Paraoxon 0.8 and Oxime 20.
There was a noticeable day effect in this as two of the Paraoxon 0.8 and the Paraoxon 0.8
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+ Oxime 20 were from two consecutive treatment days. No Paraoxon + 2-PAM rat
survived to perfusion from either of these days for comparison. No rat dosed with NIMP
and perfused at 24 hours displayed neurodegeneration.
Following this study, it was determined that measurement parameters should be
focused on examining those brains that exhibited significant neurodegeneration. For the
rats perfused at 4 days, images were taken from several high-power fields of the hilus and
CA1 regions of the hippocampus and the piriform cortex for Fluoro-Jade B
quantification. Of the animals perfused at 4 days, the only rats that displayed significant
neurodegeneration were within NIMP 0.6, paraoxon (Pxn) 0.8, and Pxn 0.8 + 2-PAM
treatment groups. Numbers of animals that displayed neurodegeneration out of these
groups were: 2 of 15 NIMP 0.6 rats, 2 of 13 Pxn 0.8 rats, and 2 of 12 Pxn 0.8 + 2-PAM
rats. No rat treated with the novel oximes displayed neurodegeneration at 4 days nor did
vehicle control animals or NIMP 0.6 + 2-PAM treated animals. The general analysis of
these animals is described in Table 2.2.
The distribution and severity of neurodegeneration in those animals displaying
positive Fluoro-Jade B staining appeared to be highly variable. Table 2.3 details the
counts by region and section of the animals that showed Fluoro-Jade B staining. It can be
observed in these counts that there is not one section or region of the brain that
consistently shows damage more than any other. Even between animals administered the
same treatment, distribution and severity of degenerating neurons was not consistent.
Possibly the best example of this is between the two NIMP treated animals. The first of
these treated on February 23 showed much more damage in the CA1 region of the -3.6
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and -4.16 sections while the other showed much less damage in this region, hardly any in
the hilus, and much more in the piriform cortex than the other animal.
Table 2.4 summarizes the counts from these animals into averages based on
treatment group. While this average decreases the variability of the observed counts to a
degree, the organophosphates still produced a variable distribution of Fluoro-Jade B
positive cells.
2.4

Discussion
Kainic acid treatment of rats verified that Fluoro-Jade B positively stains

degenerating neurons with the procedure described here. This staining was visible both at
24 hours and at 4 days post-treatment. Additionally, positive Fluoro-Jade B staining of
rats treated with organophosphates was of similar appearance to those treated with kainic
acid.
The results of the animals perfused 24 hours post-OP treatment demonstrate that
administration of paraoxon was capable of producing appreciable neurodegeneration.
While no neurodegeneration was seen with the treatment of paraoxon with 2-PAM, only
one sample was available for this group and serves as a poor indicator for the outcome of
this treatment. One animal that was treated with paraoxon and Oxime 20 displayed
significant neurodegeneration. This indicates that Oxime 20 is not fully neuroprotective
in all animals, but the incidence of this damage was much lower than with paraoxon
alone. It should be noted that a day effect might have played a role in this outcome as the
one Oxime 20 treated brain with neurodegeneration came from one of two consecutive
days in which all surviving rats, except one other that also received Oxime 20, stained
positive with Fluoro-Jade B. No rat treated with paraoxon and 2-PAM on these days
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survived to perfusion for comparison. It is likely that variability in either the
concentration of the paraoxon preparation or the susceptibility of that group of rats to
organophosphates led to this outcome. Contrary to the paraoxon data for this time point,
the lethal dose of NIMP did not produce appreciable neurodegeneration in any of the
observed samples. This is despite the animals’ seizure-like behavior appearing similar
between OPs and NIMP producing neurodegeneration at the 4 day time point at a similar
rate as paraoxon. It has been speculated that due to the pharmacokinetics of this
compound differing from paraoxon and sarin, neurodegeneration could be a more delayed
event in these animals. Alternatively, due to the smaller number of animals used in this
study, there may have not been enough power to observe the rate of neurodegeneration
produced by NIMP at a 24 hour time point. In total, 50% of animals dosed with paraoxon
alone displayed appreciable neurodegeneration while only 17% showed
neurodegeneration when Oxime 20 treatment was employed. No other treatment groups
displayed significant neurodegeneration.
The results of the 4 day time point effectively demonstrated that lethal doses of
both NIMP and paraoxon are capable of producing neurodegeneration in the rat model of
organophosphate exposure. Following NIMP exposure, 13% of rats displayed significant
neurodegeneration while with paraoxon treatment 15% of rats demonstrated significant
damage. Rats dosed with paraoxon and treated with 2-PAM displayed neurodegeneration
at a rate of 17% of rats. No rat administered NIMP with 2-PAM showed any sign of
neurodegeneration. None of the rats that were dosed with either NIMP or paraoxon and
then treated with Oxime 20 or Oxime 15 displayed any significant neurodegeneration
(Table 2.2). This is suggestive that the novel oximes afford protection against
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neurodegeneration. By controlling OP induced seizure activity from acetylcholine
accumulation, these compounds should prevent neuropathology from persistent seizures
(McDonough et al., 1995; Baille et al., 2005; Chapman, Kadar, & Gilat, 2007; Shih,
Duniho, & McDonough, 2003).
As NIMP is not a widely used surrogate of sarin exposure, these results cannot be
compared to existing literature for this compound. It can be remarked that similar to
research with other organophosphates, the neurodegeneration produced by NIMP is
variably distributed throughout several structures within the brain. Unlike this previous
work, which used male Sprague Dawley rats treated with sarin at 180 μg/kg
subcutaneously producing neurodegeneration in 98% of animals treated, the treatment of
NIMP 0.6 mg/kg subcutaneously in this study produced no neurodegeneration at the 24
hour time point and neurodegeneration in only 13% of NIMP alone treated animals at the
4 day time point (McDonough et al., 1995).
Paraoxon has been used in other published research and has been shown to
produce neurodegeneration with dosages ranging from 0.45 mg/kg to 4 mg/kg
(Finkelstein et al., 2012; Deshpande, Blair, Huang, Phillips, & DeLorenzo, 2016a;
Krishnan et al., 2016). Deshpande, Carter, Phillips, Blair, and DeLorenzo (2014b)
examined a range of doses of paraoxon alone in male Sprague Dawley rats ranging from
0.1 mg/kg to 8 mg/kg. At a dose of 0.8 mg/kg they observed 71% of treated animals
undergoing status epilepticus with a mortality rate of 50%. Doses of 2 and 4 mg/kg of
paraoxon alone produced status epilepticus at rates of 90% and 100% respectively both
with 100% mortality. In exploring a model of neurodegeneration, this study used a dose
of 4 mg/kg paraoxon. A lower dose of atropine similar to auto-injector doses decreased
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mortality by 20%, but in the interest of producing a survival model, the investigators
explored a higher dose. This dose was increased to 2 mg/kg, which when given with 25
mg/kg 2-PAM resulted in a survival rate of 50% at 24 hours. Racine scores of animals in
this study were not affected either by atropine or 2-PAM, alone or in combination. The
dosage of paraoxon used in the study described here is on the low end of doses from
published literature but higher incidences of neuropathology have been seen with lower
doses than used in this study. It could be that unknown variables make the animals in the
model used in this study more resistant to neurodegeneration necessitating the use of a
dose on the higher end of published literature. Published studies indicate that sensitivity
of rats to kainic acid, a model inducer of seizures and excitotoxic neurodegeneration, can
differ between strains of animal, so this possibility is not without basis (Golden, Smith,
Ferraro, & Reyes, 1995).
At the 4 day time point, lethal doses both of NIMP and paraoxon alone produced
neurodegeneration in a small percent of animals while no animal treated with Oxime 20
or Oxime 15 displayed evidence of neurodegeneration. Previous studies of anticonvulsant
therapy of the nerve agent soman using benzodiazepines or centrally active
anticholinergics provided evidence that control of seizure activity decreased both
incidence and severity of neuropathology in their animal model giving validity to the
assertion that attenuation of seizure activity by the novel oximes could contribute to the
lack of neurodegeneration (McDonough et al., 2000).
Comparing 24 hour and 4 day perfusion time points, NIMP only produced
neurodegeneration at the 4 day time point. As previously discussed, this could be due to a
delayed onset of NIMP induced neuropathology or a matter of study power at the 24
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hours time point. Paraoxon alone displayed neurodegeneration in 50% of animals at 24
hours and 15% at 4 days. A recent study with the sarin surrogate DFP demonstrated that
neuronal necrosis is visible as early as 12 hours after DFP exposure and persisted up to
60 days post-exposure (Siso et al., 2017). Both of the time points from the current study
fall into the range at which these changes would be present.
There were no clear differences observed in the quantity or distribution of FluoroJade B positive neurons between treatments that produced observable neurodegeneration
at the 4 day time point. This likely indicates that the anticholinergic activity and resulting
excitotoxicity display similar activities in both NIMP and paraoxon treated animals.
2.5

Conclusion
The examination of excitotoxic neurodegeneration is an important aspect of the

investigation of both the organophosphate exposure models used here and the novel
pyridinium oximes intended for the treatment of organophosphate intoxication.
Neurodegeneration is a well-documented outcome of CWA exposure, and neuronal
damage has been linked to behavioral alterations and cognitive impairment (Deshpande,
Phillips, Huang, & DeLorenzo 2014a; Myhrer et al. 2005). By examining
neurodegeneration in rats treated with NIMP and paraoxon, it is possible to compare this
model of nerve agent exposure to models using nerve agents and other nerve agent
surrogates in terms of neuronal damage. The ability of the novel oximes to attenuate
neurodegeneration serves as an important indicator of the protective potential of these
treatments. Control of OP induced seizures is critical in the prevention of
neuropathology, as persistent seizure activity from the accumulation of acetylcholine and
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glutamate is strongly associated with brain damage (McDonough et al., 1995; Baille et
al., 2005).
The data in this study support that NIMP and paraoxon have the potential to serve
as highly relevant surrogates of OP CWA induced neuropathology. In animals that
displayed significant Fluoro-Jade B staining, the distribution and severity of lesions
roughly approximated the findings of previous research using live nerve agents.
Compared to published literature, the percent of animals that showed neurodegeneration
from seizure activity was relatively low in this study. The small percent of brains in
which neurodegeneration was seen poses a practical problem in the large number of
animals that would likely be needed for statistical power, both in terms of necessary labor
and quantities of research materials. As such it might be practical to perform rangefinding studies to examine incidence and severity of neurodegenerative lesions with
various doses of NIMP and paraoxon. As indicated by previous research, higher doses of
atropine and standard use of the oxime 2-PAM in those animals not receiving the novel
oximes may be necessary for an acceptable survival rate in those animals receiving
higher OP doses while not hindering the production of neural pathology.
These initial findings of the use of Oxime 20 and Oxime 15 to prevent OP
induced neurodegeneration are promising. At the 24 hour time point, Oxime 20 greatly
reduced the percent of paraoxon animals that showed Fluoro-Jade B staining. At the 4
day time point, no animal given the novel oximes stained positive for neurodegeneration
while several that did not receive the novel oximes demonstrated measurable
neurodegeneration.
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Summary of Fluoro-Jade B data of brains of all rats dosed with either nitrophenyl isopropyl methyl phosphonate (NIMP) 0.6
mg/kg or paraoxon (PXN) 0.8 mg/kg subcutaneously with some receiving Oxime 20 (OX20) or pralidoxime (2PAM). Rats were
perfused at the 24 hour time point and brains were stained with Fluoro-Jade B. Data are grouped by treatment. The data are
expressed both as the total of all counts from all of the counted sections from each brain from each treatment group1 and the
average counts by the number of sections counted to adjust varying number of sections between treatments and regions2. Regions
selected for these counts were the hippocampus (HC), piriform cortex (PC), and amygdala (AM). Also represented are brains that
were considered TNTC (greater than 100 positive cells per region) both as a total of how many brains were TNTC3 and what
percent of brains within a treatment group were TNTC4.
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Summary of Fluoro-Jade B data of brains of all rats dosed with either nitrophenyl isopropyl methyl phosphonate (NIMP) 0.6
mg/kg or paraoxon (PXN) 0.8 mg/kg subcutaneously with some receiving Oxime 20 (OX20), Oxime 15 (OX15), or pralidoxime
(2PAM). Rats were perfused at the 4 day time point and brains were stained with Fluoro-Jade B. Data are grouped by treatment.
Includes counts expressed both as the total1 and average2 counts per brain by region as well as the standard deviation3. Also
included are total number of brains in each treatment group4, number of brains that showed appreciable damage5, and this number
expressed as a percentage6. Regions selected for these counts were the CA1 and hilus of the hippocampus and the piriform cortex
(PC).
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85
25
33
211
25
38

4/13/17
NIMP .6
4
1
117
10
1
114
21
0
95

3/20/17
PXN .8
21
62
70
8
42
95
3
36
133

4 Day Fluoro-Jade B Positive Brains – by Individual
6/8/17
PXN .8
23
106
157
14
85
151
24
98
237

3/20/17
PXN .8 +2PAM
19
53
70
9
37
84
3
35
123

3/20/17
PXN .8 +2PAM
4
31
15
5
35
31
5
17
26

Total counts of Fluoro-Jade B positive cells by section1 and region2 for each brain with appreciable damage at 4 days.
Rats were dosed with either nitrophenyl isopropyl methyl phosphonate (NIMP) 0.6 mg/kg or paraoxon (PXN) 0.8 mg/kg
subcutaneously with some receiving Oxime 20 (OX20), Oxime 15 (OX15), or pralidoxime (2PAM). Rats were perfused at the 4
day time point and brains were stained with Fluoro-Jade B. Regions selected for these counts were the CA1 and hilus of the
hippocampus and the piriform cortex (PC). Some treatments did not produce appreciable neurodegeneration and, as such, are not
represented in this table.

Table 2.3
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-4.12

-3.6

-2.8

Section1
CA1
HILUS
PC
CA1
HILUS
PC
CA1
HILUS
PC

Region2
11
26
73
48
13
74
116
13
67

NIMP .6
22
84
114
11
64
123
14
67
185

PXN .8

4 Day Fluoro-Jade B Positive Brains – by Treatment Group
PXN .8
+2PAM
12
42
43
7
36
58
4
26
75

Average number of Fluoro-Jade B counts by treatment group for 4 day animals with appreciable damage by section1 and region2.
For all groups n=2. Rats were dosed with either nitrophenyl isopropyl methyl phosphonate (NIMP) 0.6 mg/kg or paraoxon (PXN)
0.8 mg/kg subcutaneously with some receiving Oxime 20 (OX20), Oxime 15 (OX15), or pralidoxime (2PAM). Rats were perfused
at the 4 day time point and brains were stained with Fluoro-Jade B. Regions selected for these counts were the CA1 and hilus of
the hippocampus and the piriform cortex (PC). Some treatment groups did not produce appreciable neurodegeneration and, as
such, are not represented in this table.

Table 2.4

CHAPTER III
MAP KINASE GENE EXPRESSION CHANGES BY NIMP AND OXIME 1
3.1

Introduction
Organophosphates are a class of chemicals of which many are used as pesticides

while others have been employed in chemical warfare and terrorist attacks. They act as
anticholinesterases leading to a variety of signs of cholinergic toxicity including typical
nicotinic and muscarinic signs including seizures and death. Their high toxicity makes it
important to have effective drugs to use in response to human exposure. Current first-line
therapy in the U.S. consists of the anticholinergic atropine and the pyridinium oxime
pralidoxime (2-PAM). 2-PAM acts by reactivating inhibited acetylcholinesterase (AChE)
but is unable to cross the blood brain barrier. It is therefore effective at increasing
survival rate of those exposed but does not effectively prevent damage to the brain due to
seizure activity.
A series of novel pyridinium oximes with the potential to penetrate the blood
brain barrier have been developed by Dr. Howard Chambers at Mississippi State
University. Studies have been performed using a rat model to research the ability of these
compounds to reactivate AChE inhibited by a non-volatile surrogate that inhibits AChE
with the same chemical moiety as sarin, nitrophenyl isopropyl methylphosphonate
(NIMP) (Meek et al., 2012). These studies show that these compounds are able to
produce survival rates comparable to or better than 2-PAM and attenuate seizure like
behavior (Chambers et al., 2016). It is therefore believed that these oximes may have the
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potential to prevent brain damage in those exposed to high levels of organophosphates
while also producing survival rates comparable to or better than 2-PAM.
Studies exploring the changes in biological pathways that result from exposure to
OP CWAs have been performed to examine RNA expression in animal models of OP
exposure. Dillman et al. (2009) demonstrated changes in gene expression in the
hippocampus of soman exposed rats beginning at 1 hour and persisting for 7 days postexposure. Spradling, Lumley, Robison, Meyerhoff, and Dillman (2011) selected the rat
piriform cortex of seizing rats for examination of how sarin affects the transcriptional
profile based on this region’s propensity to show significant acute tissue pathology
following OP induced seizures. In this study, they documented a strong upregulation in
genes of inflammation and also saw changes in the mitogen-activated protein kinase
(MAP kinase, MAPK) system and metabolic pathways over a period of 24 hours. Work
by this same group compared gene expression of non-seizing and seizing rats exposed to
sarin, demonstrating differential regulation. Of note, they observed differences in MAP
kinase regulation, where apoptosis was promoted in seizing rats while inflammation was
suppressed in non-seizing rats (Te, Spradling-Reeves, Dillman, & Wallqvist, 2015).
Blanton, D’Ambrozio, Sistrunk, and Midboe (2003) were able to demonstrate
expressional changes in diverse genes within the hippocampus and cerebral cortex
following chronic low dose exposure to VX.
To further understand the physiological response of the CNS to administration of
the nerve agent surrogates and treatment with novel oximes, it was decided to explore
gene regulation changes resulting from exposure to these compounds. The piriform
cortex was chosen for examination as this region has been cited as a region susceptible to
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nerve agent induced damage. The MAP kinase system was selected as the genes of
interest for this study. These genes code for proteins that belong to a large group of
serine/threonine kinases that regulate cellular responses to a wide array of signals and
provide for a variety of responses including inflammation and cell differentiation,
proliferation, and death. They achieve these changes by phosphorylating other
intracellular proteins at serine/threonine amino acids. (Hommes, Peppelenbosch, & van
Deventer, 2003).
Activation of MAP kinases requires phosphorylation of both a threonine and a
tyrosine by dual specificity kinases known as MAP/ERK kinases (MEKs) or MAP kinase
kinases (MAPKKs). MEKs specifically phosphorylate Thr-Xxx-Tyr motifs of other
proteins with the X member providing further MAP kinase pathway specificity by MEKs.
As a product of this specific nature, extracellular regulated protein kinase (ERK) is only
activated by MKK1 and MKK2, c-Jun N-terminal kinases (JNK) by MKK4 and MKK7,
and p38 MAP kinase by MKK3, MKK4, and MKK6. Likewise, MEKs are controlled by
phosphorylation by specialized enzymes called MAP kinase kinase kinases (MAPKKKs
or MEKKs) (Hommes et al., 2003).
The three groups of MAPKs noted in the previous paragraph, ERK, JNK, and
p38, constitute three independent MAP kinase cascades each with specific members and
outcomes.
The ERK signal pathway controls cellular growth, proliferation, and survival and
mediates several inflammatory processes including T cell activation. ERK has two
isoforms ERK1 and ERK2 (also termed p44 and p42 respectively). These enzymes are
ubiquitously expressed and are activated by MEK1 and MEK2, which are activated by
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Raf. Duration of their activation is dependent upon regulatory dephosphorylative
mechanisms. ERK1/2 is able to act upon both transcription factor and membrane and
cytoplasmic proteins. One of their most important targets is the activating protein 1 (AP1) transcription factors, including c-Jun, c-Fos, and activating transcription factor 2
(ATF-2). ERK1/2 also phosphorylates Elk-1, another activator of c-Fos (Hommes et al.,
2003).
The JNK pathway is activated in response to cellular stress and serves to regulate
cell proliferation and apoptosis. JNK proteins have at least 10 isoforms encoded by
splicing of the genes JNK-1, JNK-2, and JNK-3 (RamaRao, Waghmare, Srivastava, &
Bhattacharya, 2010). Similar to ERK1/2, JNK is an activator of AP-1, primarily c-Jun
and ATF-2. It is activated by MKK7, in response to cytokines, and MKK4, in response to
environmental stress. Upstream activators of these MAPKKs include more than 12
intracellular proteins including MEKK1-4. There are four known negative regulators of
JNK: MAP kinase phosphatase MKP7, heat shock protein 72 (HSP72), Evil onco-protein,
and nitric oxide. JNK signaling is thought to play a role in many pathological conditions
such as cancer, stroke, heart disease, and inflammatory disorders (Hommes et al., 2003).
The p38 pathway is another mediator of inflammation and cell growth,
proliferation, and death. In regard to inflammation, p38 affects inflammatory mediators
of leukocyte recruitment and activation. This includes E-selectin and VCAM1 mediated
rolling adhesion of leukocytes and endothelial cells and regulation of TNF-α synthesis.
There are four identified isoforms, two of which (p38α and p38β) are expressed
ubiquitously. p38 is primarily activated by various cytokines but can also activate in
response to activation of Toll-like receptors by pathogens. Its upstream activators are
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MKK3, MKK4, and MKK6. Upon activation, p38 phosphorylates either other kinases of
transcription factors such as ATF-2 or myocyte enhancer factor 2 (MEF2). p38 is a
potential activator of NF-κB transcription (Hommes et al., 2003).
While the MAP kinase system has three separate pathways, there is potential for
upstream and downstream interactions between the three. Some upstream activators, such
as p21Rac, may simultaneously activate more than one MAPK pathway. On the other end
of the pathway, some targets of MAP kinase proteins can act as either kinases or
phosphatases providing either activation or deactivation of other MAPK enzymes
(Hommes et al., 2003).
Other groups have previously investigated the effects that OPs have on MAP
kinase activation. Niijima et al. (2000) were able to display an increase in
phosphorylation state of JNK, phospholipase C γ (PLC γ) and cytosolic MAPK following
treatment of rats using LD50 dosages of sarin and soman nerve agent surrogates.
RamaRao et al. (2010) demonstrated increases in the phosphorylation of JNK3 and
calcium/calmodulin-dependent protein kinase II (CaMKII) of the cerebrum,
hippocampus, and thalamus beginning 2.5 hours after soman administration and
continuing until 30 days post-exposure. Damodaran et al. (2006) showed changes in
expression of many diverse genes in brains of rats exposed to sarin both 15 minutes and 3
months after treatment. These included Camk1b, Camk2d, Map2k, CamkIIa, Jun, and
Fos. This study demonstrated changes in many other genes affecting cytokines,
neurotransmission, cell signaling, ion channels, cell cycle, apoptosis, and cell
metabolism.
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By studying changes in MAP kinase gene regulation it was hoped to better
understand how the brain responds to the nerve agent surrogates and potentially show a
sparing effect on these changes when novel oxime treatment is provided. It was expected
that the sarin surrogate NIMP would produce alterations of MAP kinase gene expression
and treatment with the novel oximes would return gene expression to levels closer to
baseline.
To study this gene expression, a standard qPCR kit developed specifically for
expression of this gene system within rats was used. The Qiagen RT2 Profiler PCR Array
MAP Kinase Signaling Pathway kit was used with the associated sample preparation kits
in order to guarantee sample consistency and compatibility with the qPCR assay. The
novel oxime chosen for this study was Oxime 1, which has been one of the most
promising oximes in studies up to this point (Chambers et al., 2016).
3.2
3.2.1

Methods
Treatments
Treatments for these animals were performed as previously described (Chambers

et al., 2013). Adult male (250-300g) Sprague Dawley rats were injected subcutaneously
with either a high sublethal dosage of the sarin surrogate NIMP (0.325 mg/kg) or vehicle
(DMSO). One hour after injection, which should represent time of peak brain AChE
inhibition of about 80%, rats were administered an intramuscular injection of either 146
μmol/kg (the human equivalent dose) of the novel Oxime 1 or vehicle (Multisol). Rats
were sacrificed 2 hours later and the piriform cortices quickly dissected, placed in an
RNAse free tube, and frozen in liquid nitrogen. Samples were stored at -80°C until total
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RNA extraction. Three brains were collected for each of the following treatments: vehicle
control, Oxime 1 control, NIMP, and NIMP plus Oxime 1.
3.2.2

RNA Isolation
Total cortex RNA was isolated using Qiagen’s RNeasy® Plus Mini Kit (Valencia,

CA) per manufacturer’s instructions. Samples were homogenized in individual tubes on
ice with RNAse free plastic grinders. Lysates were centrifuged through QIAshredder
columns to ensure complete tissue disruption followed by centrifugation through gDNA
eliminator columns to remove genomic DNA. Purity and concentration of the RNA
samples were determined by 260/230 and 260/280 absorbance ratios measured with a
Nanodrop ND-1000 spectrophotometer. Samples with concentrations higher than 40
ng/µl and an 260/230 absorbance ratio greater than 1.7 were suitable for use and
examined on bleach agarose gels for integrity of both the 28S and 18S RNAs by the
method described in Aranda, LaJoie, & Jorcyk (2012).
3.2.3

Reverse Transcription
cDNA was reverse transcribed using Qiagen’s RT2 First Strand Kit. 0.5µg of

isolated RNA was processed according to the manufacturer’s instructions for each 96
well plate PCR array. A genomic DNA elimination buffer was used prior to reverse
transcription to eliminate any remaining genomic DNA. RE3 reverse transcripase mix
was primed in an unbiased manner with random hexamers and oligo-dT primers. Samples
were stored at -20oC until performing real-time qPCR.
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3.2.4

Real-Time qPCR
Real-time qPCR was performed using Qiagen’s RT² Profiler™ PCR Array Rat

MAP Kinase Signaling Pathway (Qiagen Product no. 330231, Cat. no. PARN-061Z), a
96 well plate containing primer assays for 84 rat MAP kinase genes, 5 housekeeping
genes, 3 reverse transcription controls, 3 positive PCR controls, and one genomic DNA
control arranged as seen in Figure 3.1 (Qiagen, 2011). cDNA was combined with Qiagen
RT2 SYBR Green ROX™ qPCR Mastermix and 25µl were dispensed into each well.
Plates were amplified on a Stratagene Mx3005P® real-time cycler.
3.2.5

Data Analysis
CT values were calculated with Stratagene’s MxPro QPCR software. Threshold

was determined on the first array and kept constant on all following plates. CT values
from each array were uploaded to Qiagen’s GeneGlobe Data Analysis Center. The
application performed quality control to ensure that all controls were within acceptable
limits indicating adequate reverse transcription and PCR performance and absence of
genomic DNA. The Rplp1 gene was manually selected for data normalization due to
lowest variation between sample Ct values. Fold change was calculated to represent
normalized gene expression as (2^(- Delta Ct)). P values were calculated by Student’s ttest of the fold change values. These data were used to generate scatter and volcano plots,
heat maps, and multigroup plots for differential analysis among treatment groups.
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3.3

Results
Twelve rats were treated following the protocol described above with three rats in

each treatment group. Their piriform cortices were harvested, and total RNA was isolated
while DNA was eliminated. All RNA met the quality control standards as described in
the user manual: 260/280 absorbance ratio greater than or equal to 2, 260/230 absorbance
ratio of greater than or equal to 1.7, 40 ng/µl, and well defined 28S and 18S RNA band
on bleach agarose gel electrophoresis. Reverse transcription of RNA to cDNA was
performed and qPCR of cDNA was performed using the provided arrays. All raw data
looked acceptable based on low background signal and acceptable melting curve
appearance. Raw data were compiled and loaded into the Qiagen Data Analysis Center.
All samples met the application’s quality control standards, and the Rplp1 gene was
selected for normalization of data between plates.
From analysis of qPCR arrays, data for 84 genes of interest were generated for
each animal in this study.
In comparing the vehicle control group to the Oxime 1 control group, most of the
genes displayed very little to no change. Fold changes of interest were Map4k1 0.38, Mos
0.58 p=0.048, and Sfn 0.24 as shown in Table 3.1.
Comparing vehicle control to the NIMP treated group showed more differences in
fold gene expression changes. Most notable are Ccna2 2.68 p=0.044, Cdkn1a 2.44, and
Cdkn2a 0.12 p=0.041 (Table 3.1). An additional 9 genes displayed a fold change of less
than 0.5 but were not statistically relevant.
When the NIMP + Oxime 1 treated group is compared to vehicle, there appear to
be less genes whose expression was altered than seen with NIMP treatment alone. The
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only fold changes of note are: Kcnh8 0.26, Map4k1 0.38, Mos 0.26 p=0.006, and Sfn
0.35 (Table 3.1). The fold change of these genes of interest are displayed in Figure 3.2.
3.4

Discussion
The data generated in this study demonstrate that the sarin surrogate NIMP is able

to elicit changes in transcriptional regulation of the MAP kinase system within the
piriform cortices of rats administered a sublethal dose. These data also show that rats
treated with Oxime 1 alone have few alterations in the expression of genes within the
MAP kinase cascade. When this oxime is given in conjunction with NIMP, it attenuates
many of the changes seen with NIMP alone. Perhaps more importantly, this study
identifies the genes whose expression is altered by these compounds. These observations
can therefore give insight as to what physiologic responses might be elicited by these
compounds.
3.4.1

Oxime Treatment
The only genes that displayed notable changes in expression by Oxime 1 alone

were Map4k1, Mos, and Sfn.
3.4.1.1

Map4k1
Map4k is also known as hematopoietic progenitor kinase 1 (HPK1). It is

primarily expressed in hematopoietic organs and cells and acts in many signal systems
including MAP kinase, antigen receptors, apoptosis, growth factors, and cytokines. It can
also serve as a connection between surface receptors and JNK signaling. It can be
activated by stimulation of various receptors including T or B cell antigen receptors,
transforming growth factor-β receptor (TGF-βR), erythropoietin receptor, Fas, and E
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prostanoid receptor (Li, Han, Chen, Yu, & Zhang 2008a). It has been shown in a rat
stroke model that MAP4k1 is upregulated and knocking down MAP4k1’s activity
provides neuroprotection by decreasing activation of the MLK3-MKK7-JNK3 pathway
(Li, Yu, & Zhang 2008b). Another study by the same group demonstrated that inhibition
of Src kinase activation either by direct inhibition of Src or inhibition of NMDA
receptors decreases phosphorylation of MAP4k1, MLK3, JNK, and c-Jun. Inhibition of
this pathway provided neuroprotection when subsequent experimental cerebral ischemia
was performed (Li et al., 2008a). Work by Lasserre et al. (2011) provided evidence that
MAP4k1 is a regulator of T cell response intensity by inducing 14-3-3 protein binding
that release the signaling adaptors SLP76-GADS from the membrane reducing induced
gene transcription.
Considering these observations, it is possible that the decrease in Map4k1
expression invoked by Oxime 1 could have a neuroprotective role by ultimately
decreasing JNK activation. Another possibility is that through impairment of T cell
activation within the CNS, the brain’s response to damage might be altered. While the
CNS is generally considered to be immunologically privileged, there is growing evidence
that T cells are both present and important in the normal function of the CNS and in its
response to stressful stimuli. Studies using mouse hippocampal slices exposed to kainic
acid have demonstrated that the presence of CD4+ and CD8+ T cells improve neuronal
survival and reduce p38 and ERK activation likely through activation of astrocytes by
IFN-γ and IL-4 (Ellwardt, Walsh, Kipnis, & Zipp, 2016). It is possible that by decreasing
T cell activation, Oxime 1 could decrease the brain’s ability to properly respond to
excitotoxic neuronal stress.
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3.4.1.2

Mos
The next gene altered by Oxime 1 was Mos, the Moloney sarcoma oncogene.

Most studies to date have concentrated on the function of Mos with regard to meiotic
cells. Mos functions as an upstream activator of MAP2K1 and MAP2K2 (MEK1/2),
which are upstream activators of ERK 1 and ERK2 (Gonzalez-Garcia et al., 2014).
Depending on how ERK1/2 are activated, they can promote many cellular functions
including proliferation, cell survival, and cell death (Mebratu & Tesfaigz, 2009). During
the final stages of oocyte maturation Mos synthesis is upregulated leading to a
downstream upregulation of the MAP kinase pathway, which promotes maturation of the
oocyte (Gonzalez-Garcia et al., 2014). Perrard, Chassaing, Montillet, Sabido, and Durand
(2009) identified Mos in male meiotic cells where they noted a positive feedback
between MAP kinase and Mos. Their findings suggested a relationship between an
increase in Mos and a β-NGF induced cell cycle arrest. Kalejs et al. (2006) noted
upregulation of Mos and several other genes that the authors considered meiosis specific
in p53 mutated lymphoma cell lines. They suggested that increased Mos protein
concentrations could play a role in the metaphase arrest of mitotic catastrophe.
Despite little data on the function of Mos outside of the meiotic cell, some
inferences could be made towards what effects its downregulation may mean in the cells
of Oxime 1 treated animals. As Mos is an upstream activator of MEK1/2, decreased Mos
expression could lead to less overall MAP kinase activation down this pathway. While
mode of activation of MEK1/2 and ERK1/2 can affect the physiological outcome that
these enzymes promote, decreased Mos expression would likely be less detrimental than
increased expression. An increase would more likely promote cell death while a decrease
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might indicate cellular stasis. It is possible that decreased activation of MEK1/2 and
ERK1/2 could decrease signaling for apoptosis.
3.4.1.3

Sfn
Sfn codes for the protein 14-3-3σ, a member of the 14-3-3 protein family. These

proteins are known to be present primarily in the brain tissue of animals contribute to
neuron function. The first identified function of these proteins was as an activator of
tyrosine hydroxylase and tryptophan hydroxylase, enzymes responsible for the
production of neurotransmitters (Ferl, Manak, & Reyer, 2002). This 14-3-3 protein is
termed tyrosine hydroxylase/tryptophan hydroxylase activation protein (Furukawa et al.,
2011). They have also been detected in extracellular environments such as the
cerebrospinal fluid (Hermeking, 2004). 14-3-3s can interact with ASK1 to inhibit
apoptosis (Kim, Khursigara, Sun, Franke, & Chao, 2001). Structurally these proteins
have a highly conserved core region that serves as the proteins’ functional region and
divergent amino and carboxyl termini. Ligands to which the core region binds are often
phosphorylated at a serine or threonine residue in the target sequence, but this is not
always the case. Another protein in the MAP kinase cascade, Raf-1, is also a 14-3-3
protein (Ferl et al., 2002).
14-3-3σ expression was initially observed in differentiating epithelial cells where
its expression is induced when keratinocytes are exiting the stem cell compartment
(Hermeking, 2004). More than 100 ligands have been identified for this protein affecting
many cellular processes including cell proliferation, cell cycle regulation, and apoptosis.
Its expression is regulated by p53 and BRCA1 (Li, Liu, & Zhang, 2009). Exogenous
expression of this protein results in inhibited G2/M progression. The mechanism of 14-3-

47

3σ G2 arrest in cases of DNA damage begins with Rad3-dependent activation of Chk1
kinase, which phosphorylates Ser-216 of Cdc25C phosphatase. This phosphorylated
serine serves as a binding site for 14-3-3σ. Binding of Cdc25C sequesters this enzyme
out of the nucleus preventing it from dephosphorylating Cdc2, a cyclin-dependent kinase
required for entry into mitosis. DNA damage has been shown to increase p53 mediated
upregulation of 14-3-3σ, and exogenously delivered p53 produced a pronounced increase
of Sfn RNA. Several indicators support that experimentally increased 14-3-3σ protein
concentration produces a G2 arrest. This cell cycle block can be uncoordinated with DNA
synthesis proceeding between mitoses. It is thought that this loss of coordination might be
due to lack of p21 modulation. In cases of DNA damage both 14-3-3σ and p21 are
activated with p21 preventing DNA synthesis through inhibition of cyclin-dependent
kinases (Hermeking et al., 1997). Epigenetic suppression of Sfn is seen in many
carcinomas giving rise to the belief that it is a tumor-suppressive gene. Experimental
removal of this gene removes the ability of cells to maintain a stable G2/M arrest
following DNA damage (Hermeking, 2004). Evidence also exists for post-transciptional
regulation of 14-3-3σ, possibly a product of mRNA stability, translational efficiency, and
protein stability. This leads to the assumption that regulation of 14-3-3σ takes place at
multiple levels (Li et al., 2009). In human gliomas, the degree of Sfn expression
downregulation has been correlated with disease prognosis (Deng et al., 2011).
In Oxime 1 treated animals, the fold change in Sfn expression decreased to 0.58.
This could indicate that Oxime 1 might alter some of the normal functions of neurons
such as production of neurotransmitters. This could potentially alter the amount of
neurotransmitter available to continue neuronal signals. It is possible that this could be
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protective in the face of excitotoxicity. The lack of 14-3-3σ could be detrimental in
cellular response to damage and could promote either development of neoplasia or
continuance through the cell cycle promoting apoptosis.
3.4.2

NIMP Treatment
More genes were altered by NIMP administration than Oxime 1. Of most interest

were Ccna2, Cdkn1a, and Cdkn2a. Contrary to what was seen in Oxime 1 treated
animals, Mos was observed to increase with NIMP alone treatment.
3.4.2.1

Ccna2
NIMP treatment significantly increased Ccna2 levels by 2.68 fold. Ccna2 (cyclin

A2) serves to regulate cell cycle at mitosis and interphase by interacting with cyclindependent kinases 1 and 2 (Cdk1 and Cdk2). Most cyclin A2 is degraded either by the
ubiquitin system or by autophagy before mitosis occurs. This is necessary for alignment
of chromosomes and progression into anaphase (Loukil et al., 2016). Additionally, cyclin
A2 promotes activation of Rho signaling molecules that control cell morphology,
motility, and cytokinesis. In the absence of cyclin A2, RhoA activity decreases producing
increased cell motility and invasiveness. Increased RhoA is necessary at the end of
mitosis in order to form the cleavage furrow. It localizes at the poles of the furrow while
the remaining cyclin A2 aligns between these poles across the cleavage furrow (Loukil et
al., 2016). This protein also serves as a regulator of G1 to S phase transition in the cell
cycle as well as G2 to M (Fung, Ma, & Poon, 2007; Gygli et al., 2016). Knockdown of
Ccna2 expression delays entry into mitosis. Cyclin A cannot drive mitosis by itself and
requires cyclin B to push the cell into mitosis (Fung et al., 2007). Cyclin A2 has also been
implicated in DNA damage response. It can be found located at sites of DNA double49

strand breaks serving for repair of the break either through homologous recombination or
non-homologous end joining. Mice lacking cyclin A2 had deficient repair of neuronal
DNA (Gygli et al., 2016). Cyclin A2 overexpression can cause premature entry and
prolongation of S phase as well as induce double strand breaks of the DNA (Tane
&Chibazakura, 2009). A study by Seidel et al. (2011) showed that Ccna2 gene expression
increases in a rat cerebral ischemia model, likely as a result of decreased promyelocytic
leukemia zinc finger (PLZF) protein levels. A study of gene expression in a rodent spinal
cord model by Wu et al. (2014) showed that cyclin genes such as Ccna2 show increased
expression in the cerebral cortex and hippocampus.
The increase seen in Ccna2 as a product of NIMP administration could have
several potential explanations. One of the more likely would be that the stresses the
neurons face from increased cholinergic stimulation and seizure activity could lead to
perturbations of the cell cycle including: neurogenesis, increased cell cycle, or apoptosis.
Another possibility could be that the OP might induce DNA damage to which Ccna2
synthesis is increased in response.
3.4.2.2

Cdkn1a
Cdkn1a gene expression was also elevated following NIMP administration. This

gene encodes a protein, p21, that inhibits cyclin/cyclin-dependent kinase (CDK)
complexes helping to regulate cell-cycle transitions. It is able to interact with almost any
CDK complex. Its mechanism is not always inhibitory and in some cases such as
CDK4/6 it can even be stimulatory. It can also target molecules other than CDKs
including MEKK5 and CK2 kinases, calmodulin, GADD45, procaspase 3, and oncogenic
protein SET. By binding proliferating cell nuclear antigen (PCNA) Cdkn2a can interfere
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with DNA replication. Cdkn2a can also affect transcription by inhibiting E2F, Myc, and
STAT3 or stimulating NFκB –mediated transcription. p21 expression is increased in
different cells by stress stimuli such as DNA damage, agents that affect DNA synthesis or
mitosis, TGFβ, and differentiating or oncogenic chemicals (Roninson, 2002). It is
considered to be the primary mediator of G1 arrest due to DNA damage. It is also
important in the G2-phase checkpoint as well (Cazzalini, Scovassi, Savio, Stivala, &
Prosperi, 2010). Cdkn1a increase is due to changes in transcriptional activation and
mRNA and protein stability. This increase is transient indicating that p21 is likely only
involved in the early stages of cell cycle arrest. Cdkn1a, along with Cdkn2a and p53, is
involved in accelerated cellular senescence induced by DNA damage or telomere
shortening (Roninson, 2002) Both Cdkn1a and Cdkn2a are upregulated in response to
aberrant mitotic progression (Dikovskaya et al., 2015).
One major function of Cdkn1a is as an anti-apoptotic factor. This is due to
interactions with several molecules including: binding procaspase 3 to prevent its
conversion to caspase 3, interacting with caspases 8 and 10, inhibiting apoptosisregulating kinases, and inhibiting apoptosis-stimulating kinases Myc and E2F. It is
cleaved by caspase 3 at the beginning of apoptosis to remove this suppression (Roninson,
2002). Other sources have reported that p21 can serve in a pro-apoptotic role as well. Cell
models that over express p21 directly or through increased p53 activation of p21 induce
apoptosis. p21-null primary hepatocytes have also been shown to display less apoptosis
when challenged than wild-type (Liu, Bishop, & Liu, 2003). In one study with squamous
carcinoma cells mutated to overexpress p21, this protein was shown to either be pro- or
anti-apoptotic depending on which chemotherapeutic was administered. Subcellular
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localization likely plays a part in this differential action. Cytoplasmically p21 can block
activation of caspase and pro-apoptotic MAP kinase proteins, but inside the nucleus it
favors apoptosis due to DNA damage (Cazzalini et al., 2010).
As mature neurons maintain a quiescent state throughout their life, alteration of
their cell cycle regulation can be detrimental. Reentry into the cell cycle by mature
neurons is associated with cell death. In Alzheimer’s disease models, re-expression of
cell cycle genes is seen prior to neuronal death. This alteration in cell cycle machinery
does not appear to be sufficient for neuronal death but may be a priming event for
neurodegeneration (Kawauchi, Shikanai, & Kosodo, 2013).
Due to the diverse nature of p21 as a cellular regulator, interpretation of increased
Cdkn1a gene expression is difficult. Given the static nature of mature neurons, any
alteration of cell cycle machinery is likely detrimental. If nothing else, the change in p21
regulation could serve as a primer for neurodegeneration or neurodegenerative diseases.
It could be that Cdkn1a is upregulated to either serve as an apoptosis inducer or in an
attempt to prevent cellular apoptosis. Finally, it is possible that NIMP could be causing
DNA damage either through direct interaction or cellular stress, and this is promoting an
upregulation in Cdkn1a in response.
3.4.2.3

Cdkn2a
Like Cdkn1a, Cdkn2a codes for a CDK inhibitor, p16. It acts as a negative

regulator of cell cycle (Zhao, Choi, Lee, Bode, & Dong 2016). Binding of p16 to CDK4
or CDK6 prevents these proteins from complexing with cyclin D interfering with this
controller of G1 phase proliferation (Serrano, Hannon, & Beach, 1993). Lack of the
CDK6/4-cyclin D complex promotes G1 arrest through lack of the Rb/E2F complex
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(Zhao et al., 2016). In astrocytes, increased p16 expression is observed in cellular
senescence and may be a contributor to Alzheimer’s disease (Bhat et al., 2012).
p16 additionally serves as a potential tumor suppressor and its inactivation is
increasingly seen with the advancing stages of cancer progression (Zhao et al., 2016).
Methylation of Cdkn2a is frequently seen in myelodysplastic syndrome. This methylation
was correlated with levels of cellular oxidative stress in the form of reactive oxygen
species (Goncalves et al., 2016). Inactivation of Cdkn2a is a common feature of nonsmall-cell lung cancer resultant of smoke exposure (Tam et al., 2013). Astrocytic gliomas
also underexpress Cdkn2a among other cell cycle genes with progressively more
deregulation with increasing tumor grade (Ferreira et al., 2015). Similarly, suppression of
Cdkn2a and other cell cycle genes was observed in meningiomas (Bostrom et al., 2001).
In a cerebral ischemia model, p16 was observed to be downregulated in neurons
following ischemia and reperfusion. By using multiple labels for p16, MAP-2, and
TUNEL, researchers were able to show that at 9 hours after ischemia p16 staining
decreases even before any TUNEL labeling becomes apparent. As time progressed,
TUNEL labeled cell numbers increased while the number of intact p16 negative cells
decreased. At 72 hours, all remaining morphologically intact MAP-2 labeled cells were
p16 positive. This study supports that p16 regulation precedes neuronal cell death
(Katchanov et al., 2001).
Cdkn2a encodes an alternate open reading frame that produces the protein p19
that interacts with the p53 pathway (Zhao et al., 2016). p19 helps to coordinate the selfrenewal and determination of neuronal and glial fate of neuronal stem cells. Inactivation
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or forced expression of p19 can alter the stage of these cells, changing their functions and
fates (Nagao et al., 2008).
In this model, treatment with NIMP produces a significant decrease in Cdkn2a
expression. Decrease in Cdkn2a expression removes inhibition on CDK complexes
promoting cell cycle. Reentry of mature neuronal cells into the cell cycle leads to cell
death, and as noted above, decreased p16 expression has been implicated as a preceding
event to apoptosis. Alternate interpretations could be that changes to the astrocyte
population resulting from NIMP exposure could resemble the changes that occur during
senescence that would be mediated by p16. Additionally, Cdkn2a transcription could be
for p19. In that case, the seizure activity generated by NIMP could be promoting
neurogenesis from the stem cell population and therefore calling for changes in p19
regulation.
3.4.2.4

Mos
The physiology of Mos has been described earlier in this chapter. As opposed to

Oxime 1, NIMP provided for an increase in Mos expression. With Mos being an
upstream activator of MEK1/2 and ERK1/2, this increase will most likely promote
signaling down this pathway. Activation of this pathway has various outcomes including
cell proliferation, cell survival, and cell death. It is possible that Mos activation could be
a compensatory mechanism to promote cell survival in the face of excitotoxicity.
Alternately it could be promoting reentry into the cell cycle of mature neurons and
cellular apoptosis.
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3.4.3

NIMP + Oxime 1 Treatment
Oxime 1 treatment following NIMP produced a return toward baseline in several

of the genes whose expression had been altered by NIMP, Ccna2, Cdkn1a, and Cdkn2a.
It also mirrored the changes in Map4k1, Mos, and Sfn that were seen by Oxime 1 alone
treatment. Additionally, Kcnh8 and Kcnn1 showed alterations more extreme than either
NIMP or Oxime 1 alone.
3.4.3.1

Ccna2
In rats treated with NIMP and Oxime 1, Ccna2 is not upregulated as with NIMP

treatment alone. Its expression is close to that of the control. This likely indicates that the
alterations of cell cycle such as neurogenesis or apoptosis caused by NIMP treatment are
not seen in animals that also receive Oxime 1 therapy. This promotes the view that
Oxime 1 is protective against NIMP exposure.
3.4.3.2

Cdkn1a
While Cdkn1a was not significantly upregulated in the NIMP alone treated rats,

its mean was more than two times that of control. With Oxime 1 treatment, this value
returned to much closer to baseline. Due to the multitude of processes regulated by
Cdkn1a, it is difficult to predict what changes that NIMP produced that Oxime 1 might be
affecting. It does demonstrate that Oxime 1 attenuates some responses of the rat brain to
NIMP administration.
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3.4.3.3

Cdkn2a
Unlike the previous genes, the transcription of Cdkn2a was significantly

decreased by NIMP administration. Oxime 1 treatment in addition to NIMP returns this
value to closer to baseline. As decrease of this CDK inhibitor promotes entry into the cell
cycle, the return towards baseline likely indicates that Oxime 1 treatment is lessening the
stimulation of mature neurons to reenter the cell cycle. This would mean these cells are
less likely to undergo neurodegeneration promoting the theory that Oxime 1 therapy is
protective against OP induced neuronal damage.
3.4.3.4

Map4k1
As with Oxime 1 alone treatment, Oxime 1 + NIMP treated animals still see a

similar decrease in Map4k1 when compared to control. It is likely that this depression
could be neuroprotective through suppression of JNK activation.
3.4.3.5

Mos
When NIMP and Oxime 1 are administered together, expression of Mos

significantly decreases, even more so than when only Oxime 1 is given. The reason for
this additive effect is not readily apparent as NIMP alone produces an increase in Mos
expression. The decrease in Mos will lessen activation of MEK1/2 and ERK1/2, which
might promote cellular stasis. This stasis might be neuroprotective in the fact of
excitotoxicity induced by NIMP.
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3.4.3.6

Sfn
Oxime 1 + NIMP treated animals demonstrate a similar decrease in Sfn to Oxime

1 treated rats. This indicates Oxime 1, whether with or without NIMP treatment produces
some similar changes in the normal function of the cells, which could be potentially
detrimental to survival.
3.4.3.7

Kcnh8
Kcnh8 saw a decrease in expression following administration of both NIMP and

Oxime 1 while not being as strongly affected by either compound alone. Kcnh8 encodes
for elk, a subfamily of the EAG family of potassium channel pore-forming subunits. All
of the known members of this family form potassium channels that function at either
subthreshold or near threshold voltages. Some of these channels are always active and
can contribute to steady outward currents during long depolarizations. Even those that are
able to inactivate, a portion of their current never inactivates. Aside from elk, there are
two other EAG subfamilies, eag and erg. Subunits of these subfamilies are only able to
interact with subunits of the same family producing heteromultimeric channels with
various functional properties. This variety of channels produces an M-like current that is
a complex combination of ion channels (Saganich, Machado, & Rudy, 2001).
By decreasing Kcnh8 expression, NIMP and Oxime 1 could produce alterations in
the membrane excitability of neurons. While unlikely to produce changes severe enough
to affect excitotoxicity, the potential changes to resting neuron voltage and length of
depolarization, could alter mental capacity and behavior in those exposed.
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3.4.3.8

Kcnn1
Kcnn1 also decreased more when rats were treated with both NIMP and Oxime 1

than with either compound alone. Kcnn1 codes for SK1, a member of the SK family of
calcium-activated potassium channels. SK1 alone is not able to form functional
homomeric units (D’hoedt, Hirzel, Pedarzani, & Stocker, 2004). When SK1 and SK2 are
both expressed, current magnitude is increased, and the channels are less sensitive to
blocking agents indicating a functional interaction between these two subunits (Benton et
al., 2003) In a neurotoxic model of Parkinson’s disease, increased neuronal firing was
associated with an increase in SK channel activity. Neurotoxicity in this model was
indicated to be a product of SK channel changes (Wang et al., 2015).
While Kcnn1’s product, SK1, does not form a functional channel on its own, it is
able to interact with related subunits to form potassium channels able to alter the
magnitude of nerve conductances. Experimental data indicate that these channels alter
neuronal firing patterns and might contribute to excitotoxicity. With a decrease in
expression, treatment with these compounds may lead to alterations of neural firing,
which could lead to behavioral changes following treatment. Considering that expression
is depressed, which would likely decrease conductance magnitude, this change could
potentially be protective against excitotoxicity.
3.5

Conclusion
Examination of MAP kinase gene expression in the rat piriform cortex provides

evidence that administration of both Oxime 1 and sublethal NIMP cause alterations in the
transcription of several genes involved in cell signaling and the cell cycle. Additionally,
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treatment of NIMP exposure with Oxime 1 was able to attenuate some of the changes in
gene regulation
While Oxime 1 is intended as an antidote to organophosphate poisoning, its
presence within the tissue leads to the possibility that it could have physiological effects
even in the absence of these compounds. Generally the alteration of MAP kinase
transcription was less pronounced in this group than the other examined treatments, but
the expression of Map4k1, Mos, and Sfn were decreased with Oxime 1 treatment.
Decreased Map4k1 expression could possibly be neuroprotective by decreasing
activation of JNK, but it is also possible that by having lower concentrations of Map4k1,
T cell activation might be impaired, potentially limiting the brain’s natural response to
excitotoxic stress. Mos is an upstream activator of MEK1/2 and ERK1/2. By decreasing
its expression, activation of the downstream MAP kinase enzymes might be decreased
with various effects dependent upon the exact mode of activation. It is possible that the
decreased activation of this pathway could be neuroprotective by decreasing signaling for
apoptosis. Decreased Sfn could have several potential outcomes. One of its roles is in the
production of the neurotransmitters serotonin and dopamine. It is possible that the
decrease in the availability of these neurotransmitters resulting from decreased Sfn
expression could be somewhat protective when faced with excitotoxicity. Another
possible effect would be that alterations of the cell’s ability to undergo G2 arrest could
promote either apoptosis or neoplasia in the absence of this normal safeguard.
The general theme of genes whose expression was altered by NIMP exposure was
control of cell cycle and apoptosis. Both the observed increase in Ccna2 and Cdkn2a
would suggest that neurons are being regulated into continuing through the cell cycle. In
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mature neurons this would likely indicate that they were being directed towards
apoptosis. In cells that are not terminally differentiated it could mean that the cells might
be undergoing neurogenesis in response to cellular stress. The increase in Cdkn1a is less
clear-cut as, depending on the circumstances, this regulation might either promote or
hinder apoptosis. This could mean that either this regulation is assisting in promoting cell
death, or alternatively, it could be a compensatory mechanism to promote cell survival.
The final gene effect by NIMP alone, Mos, is an upstream regulator of MEK1/2 and
ERK1/2. Since NIMP increases Mos expression, activation of these other proteins should
increase producing changes in signaling for cell proliferation, cell survival, and cell
death. Considering this, like Cdkn1a, Mos could have more than one function. It is
possible that increased expression of this gene could promote cell survival and oppose
apoptosis. It could also be that this increased expression will promote apoptosis and
contribute to neurodegeneration from NIMP exposure.
When NIMP exposed rats are subsequently treated with Oxime 1, several of the
genes that showed major alterations in expression returned toward baseline. These
included Ccna2, Cdkn1a, and Cdkn2a. Also, like Oxime 1 alone treatment, Map4k1,
Mos, and Sfn were decreased. Finally, Kcnh8 and Kcnn1, which were not changed with
either NIMP or Oxime 1 alone, decreased when exposed to both compounds. The return
toward baseline of Ccna2, Cdkn1a, and Cdkn2a promotes the idea that Oxime 1 is
protective against NIMP induced excitotoxicity, producing less cellular signaling for
entry into the cell cycle and apoptosis. Alteration of Map4k1, Mos, and Sfn regulation
similar to Oxime 1 treatment alone suggests that Oxime 1 does have physiological effects
of its own that are independent of its function to combat organophosphate binding of
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AChE. The fact that treatment with NIMP and Oxime 1 together produces a more
significant change in Kcnh8 and Kcnn1 than either compound alone suggests that these
compounds can have an additive effect to alter cellular activity. As both of these genes
produce potassium channels, it is likely that the change in their expression would alter
membrane excitability and function possibly affecting neuronal function and behavior in
the future.
The results of this study provide evidence that like CWA organophosphates,
NIMP is able to produce alterations of gene expression. In all of these previous studies,
MAP kinase alterations were noted (Damodaran et al., 2006; Dillman et al., 2009;
Spradling et al., 2011; Te et al., 2015). By investigating MAP kinase gene expression,
this study not only demonstrated that NIMP alters cellular signaling and Oxime 1
attenuates some of these changes, but also provided insight into what downstream effects
might result from these changes. These data support that NIMP promotes reentry into the
cell cycle, likely by promoting apoptosis, but also possibly through induction of
neurogenesis as a stress response. It demonstrates that Oxime 1 is protective against this
signaling while also having some physiological effects of its own and even having
additive effects when given in the presence of NIMP.
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Fold Changes in Expression of Select MAP Kinase Genes by Treatment

Data on fold change of MAP kinase genes relative to vehicle control for all other treatments. Vehicle control value = 1.0. Fold
change was calculated to represent normalized gene expression as (2^(- Delta Ct)).

Figure 3.2
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CONCLUSION
With the significant toxicity and the widespread use of organophosphates in
agriculture and potential for use in chemical warfare, these compounds pose a major
public health concern. This is made even more concerning by the fact that there is not yet
a treatment that is fully protective against central nervous system damage resulting from
exposure to these chemicals. The novel pyridinium oximes developed by Dr. Howard
Chambers have shown promise as potential therapeutics against organophosphate
exposure, not only producing survival rates in animal models comparable to or better than
2-PAM but also reactivating inhibited AChE within the CNS and decreasing the duration
of seizures. It is hoped that attenuation of seizure activity within the brain will prevent
neuronal damage and the resulting mental alterations.
The results of the study described here are supportive of this theory that the novel
oximes might be able to prevent organophosphate-induced neurodegeneration. Rats
administered a lethal dose of paraoxon and treated with Oxime 20 had a lower incidence
of neurodegeneration than rats receiving only paraoxon 24 hours after exposure. In rats
perfused 4 days after this same exposure, no rat treated with Oxime 20 or Oxime 15
showed any sign of neural pathology while rats given only NIMP or paraoxon or
paraoxon and 2-PAM stained positively for Fluoro-Jade B. These findings support that
the novel oximes may be able to prevent excitotoxic neurodegeneration from OP
exposure, which is an important component in treating OP exposure and preventing longlasting cognitive impairment.
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The molecular work from this study also explores the alterations in genomic
regulation of the MAP kinase system as a result of both the nerve agent surrogate NIMP
and Oxime 1. The ability of Oxime 1 to return changes in gene expression back towards
baseline is supportive that this therapy is effective in attenuating organophosphate
induced seizures. The changes that are seen in MAP kinase regulation as a result of
NIMP treatment suggest that the primary effect of this OP with regards to MAP kinase is
the induction of changes in the cell cycle. These changes have several interpretations as
to their eventual outcome, but it is suggestive that the OP promotes apoptosis of the
neurons of the piriform cortex. Oxime 1 alone produces changes in MAP kinase
regulation that could lead to changes in neuronal excitability, neurotransmitter synthesis,
apoptotic signaling, and cell cycle. The study of MAP kinase RNA regulation is an
important area as this system controls various cellular responses to external stimuli.
These findings support the concept that treatment with NIMP promotes apoptosis of cells
within the central nervous system and that Oxime 1 attenuates this effect. The findings
that Oxime 1 itself produces alterations of genomic expression are not fully unexpected
but are of interest.
The model of OP exposure used in the Fluoro-Jade B study described here were
proof of concept that both NIMP and paraoxon are capable of producing
neurodegeneration in the rat model. Refinement of this model will likely be necessary in
order to produce a higher incidence of neurodegeneration in test animals as currently only
a small portion of those animals treated with the OPs developed neuropathology
observable with Fluoro-Jade B. This makes attainment of statistical power difficult, as a
high number of replications would be necessary to test for significance.
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Future directions for these projects could be refinement of the OP exposure model
to increase the rate at which animals show neurodegeneration, exploration of other
biomarkers for observation of neuropathology that may be more sensitive to seizure
induced stress, and further studies into the MAP kinase system such as protein
phosphorylation, which may prove to be a better indicator of the activity within this
system.
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